Q4 2015 13F Holders as of 31 Dec 2015
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Market price (% of par)
-
155.03%
-
Total 13F principal
-
$245,621,600
-
Principal change
-
-$2,389,570
-
Total reported market value
-
$382,007,000
-
Number of holders
-
22
-
Value change
-
+$2,451,786
-
Number of buys
-
13
-
Number of sells
-
7
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q4 2015
As of 31 Dec 2015,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$245,621,600
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, CAMDEN ASSET MANAGEMENT L P /CA, WOLVERINE ASSET MANAGEMENT LLC, Allianz Asset Management AG, CITADEL ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, DEUTSCHE BANK AG\, BASSO CAPITAL MANAGEMENT, L.P., Calamos Advisors LLC, and WELLS FARGO & COMPANY/MN.
This page lists
22
institutional bondholders reporting positions
for the Q4 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.